
## Lidija Bach-Rojecky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9374516/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Personalized Anesthetic Pharmacology. , 2021, , 65-92.		3
2	What have we learned about antinociceptive effect of botulinum toxin type A from mirror-image pain models?. Toxicon, 2020, 185, 164-173.	0.8	5
3	Resolving Issues About Efficacy and Safety of Low-Dose Codeine in Combination Analgesic Drugs: A Systematic Review. Pain and Therapy, 2020, 9, 171-194.	1.5	5
4	Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. Pharmacogenomics, 2020, 21, 141-156.	0.6	39
5	Basic Science of Pain and Botulinum Toxin. , 2020, , 113-129.		0
6	Botulinum toxin type A: Basic pharmacological profile and therapeutic applications. Arhiv Za Farmaciju, 2020, 70, 10-19.	0.2	0
7	Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 2019, 11, 459.	1.5	123
8	Challenges in anesthesia personalization: resolving the pharmacogenomic puzzle. Personalized Medicine, 2019, 16, 511-525.	0.8	8
9	Continuing war on pain: a personalized approach to the therapy with nonsteroidal anti-inflammatory drugs and opioids. Personalized Medicine, 2019, 16, 171-184.	0.8	18
10	Role of central versus peripheral opioid system in antinociceptive and antiâ€inflammatory effect of botulinum toxin type A in trigeminal region. European Journal of Pain, 2018, 22, 583-591.	1.4	28
11	Meningeal extravasation, efficacy of botulinum toxin or triptans is not specific for pathophysiology of migraine only. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-2-34.	0.0	0
12	Antinociceptive action of botulinum toxin type A in carrageenan-induced mirror pain. Journal of Neural Transmission, 2016, 123, 1403-1413.	1.4	20
13	Association of antinociceptive action of botulinum toxin type A with GABA-A receptor. Journal of Neural Transmission, 2014, 121, 665-669.	1.4	37
14	Antinociceptive effect of botulinum toxin type A on experimental abdominal pain. European Journal of Pharmacology, 2014, 745, 190-195.	1.7	9
15	Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology, 2013, 70, 331-337.	2.0	52
16	Central Action of Peripherally Applied Botulinum Toxin Type A on Pain and Dural Protein Extravasation in Rat Model of Trigeminal Neuropathy. PLoS ONE, 2012, 7, e29803.	1.1	89
17	Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience, 2011, 186, 201-207.	1.1	176
18	Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injection. European Journal of Pharmacology, 2010, 633, 10-14.	1.7	108

LIDIJA BACH-ROJECKY

#	Article	IF	CITATIONS
19	Lasting reduction of postsurgical hyperalgesia after single injection of botulinum toxin type A in rat. Fundamental and Clinical Pharmacology, 2010, 24, 43-45.	1.0	11
20	Central origin of the antinociceptive action of botulinum toxin type A. Pharmacology Biochemistry and Behavior, 2009, 94, 234-238.	1.3	122
21	Lack of antiâ€inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundamental and Clinical Pharmacology, 2008, 22, 503-509.	1.0	37
22	Reduced Brain Antioxidant Capacity in Rat Models of Betacytotoxic-Induced Experimental Sporadic Alzheimer's Disease and Diabetes Mellitus. Neurochemical Research, 2007, 32, 1709-1717.	1.6	36
23	Botulinum toxin type A in experimental neuropathic pain. Journal of Neural Transmission, 2005, 112, 215-219.	1.4	81
24	Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croatian Medical Journal, 2005, 46, 201-8.	0.2	60
25	Influence of ethanol on the myorelaxant effect of diazepam in rats. Acta Pharmaceutica, 2005, 55, 115-22.	0.9	4
26	The antidepressant activity of Hypericum perforatum L. measured by two experimental methods on mice. Acta Pharmaceutica, 2004, 54, 157-62.	0.9	16
27	Analgesic effect of caffeine and clomipramine: a possible interaction between adenosine and serotonin systems. Acta Pharmaceutica, 2003, 53, 33-9.	0.9	1